- Home
- BLFS vs ZYME Comparison
BLFS vs ZYME Comparison
Compare BLFS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLFS
- ZYME
- Stock Information
- Founded
- BLFS 1987
- ZYME 2003
- Country
- BLFS United States
- ZYME United States
- Employees
- BLFS N/A
- ZYME N/A
- Industry
- BLFS Medical/Dental Instruments
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- BLFS Health Care
- ZYME Health Care
- Exchange
- BLFS Nasdaq
- ZYME Nasdaq
- Market Cap
- BLFS 1.2B
- ZYME 968.5M
- IPO Year
- BLFS 1989
- ZYME 2017
- Fundamental
- Price
- BLFS $25.59
- ZYME $15.87
- Analyst Decision
- BLFS Strong Buy
- ZYME Buy
- Analyst Count
- BLFS 7
- ZYME 7
- Target Price
- BLFS $30.86
- ZYME $20.00
- AVG Volume (30 Days)
- BLFS 423.5K
- ZYME 448.4K
- Earning Date
- BLFS 11-11-2025
- ZYME 10-30-2025
- Dividend Yield
- BLFS N/A
- ZYME N/A
- EPS Growth
- BLFS N/A
- ZYME N/A
- EPS
- BLFS N/A
- ZYME N/A
- Revenue
- BLFS $93,468,000.00
- ZYME $122,867,000.00
- Revenue This Year
- BLFS $26.07
- ZYME $107.76
- Revenue Next Year
- BLFS $16.86
- ZYME $2.35
- P/E Ratio
- BLFS N/A
- ZYME N/A
- Revenue Growth
- BLFS 68.16
- ZYME 95.94
- 52 Week Low
- BLFS $19.10
- ZYME $9.03
- 52 Week High
- BLFS $29.55
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- BLFS 54.16
- ZYME 63.86
- Support Level
- BLFS $25.17
- ZYME $15.49
- Resistance Level
- BLFS $27.52
- ZYME $16.37
- Average True Range (ATR)
- BLFS 0.84
- ZYME 0.69
- MACD
- BLFS -0.14
- ZYME 0.07
- Stochastic Oscillator
- BLFS 36.76
- ZYME 77.08
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.